Retatrutide je inovativn experimentln peptid, kter psob jako trojit agonista receptor GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) a glukagonovho receptoru
[DOI] [PubMed] [Google Scholar] 9.Filippatos T, Milionis HJ
24 BourgonjeA
Start your intake Approved GLP-1 Injection Sites and Anatomy The FDA-cleared injection sites for GLP-1 therapy include three primary locations: the lower abdomen (avoiding a 2-inch circle around the navel), the front and outer surfaces of the thigh, and the back of the upper arm
These agents mimic GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying to improve glycemic control, as indicated by reduced HbA1c level, a crucial measure in diabetes care [2, 3]
doi: 10.1186/s10020-024-00817-8 92 SelvarajSKellyDPMarguliesKB